Shopping Cart
Remove All
Your shopping cart is currently empty
Veltuzumab
(Synonyms: IMMU-106, IMMU106, hA20) Copy Product Info
🥰Excellent
Synonyms: IMMU-106, IMMU106, hA20
Catalog No. T76765 Copy Product Info
🥰Excellent
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody that displays anti-proliferative, apoptotic, and antibody-dependent cytotoxic effects in vitro and inhibits tumor growth in mice harboring human lymphomas, and is indicated for use in non-Hodgkin's lymphoma (NHL).
Cas No. 728917-18-8
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $197 | In Stock | In Stock | |
| 5 mg | $463 | In Stock | In Stock | |
| 10 mg | $742 | - | In Stock | |
| 25 mg | $1,120 | - | In Stock | |
| 50 mg | $1,490 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:97.7% (SDS-PAGE); 97.9% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody that displays anti-proliferative, apoptotic, and antibody-dependent cytotoxic effects in vitro and inhibits tumor growth in mice harboring human lymphomas, and is indicated for use in non-Hodgkin's lymphoma (NHL). |
| Targets & IC50 | Daudi cells:0.08-0.09 μg/mL (EC50) |
| In vitro | Veltuzumab was effective in reducing dissociation rates in human lymphoma cell lines and enhancing complement-dependent cytotoxicity in 1 of 3 cell lines, but did not exhibit other significant in vitro differences. [1] Veltuzumab (0.001-10 μg/mL, 3 hours) had low EC50 values ranging from 0.08-0.09 μg/mL in Daudi cell lines. [1] |
| In vivo | Veltuzumab (intravenous or subcutaneous; 5, 20, and 60 μg; single dose) achieves control of tumor growth, or removal of circulating and adherent B cells, at low doses in mouse models. [1] Veltuzumab (intraperitoneal; 0.05-35 μg) demonstrated significant efficacy in in vivo studies. [1] |
| Synonyms | IMMU-106, IMMU106, hA20 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | CD20 |
| Molecular Weight | 145.33 kDa |
| Cas No. | 728917-18-8 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: Veltuzumab chemical structure | Veltuzumab in vivo | Veltuzumab in vitro | Veltuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.